Ocugen, Inc. (OCGN)
OCGN Stock Price Chart
Explore Ocugen, Inc. interactive price chart. Choose custom timeframes to analyze OCGN price movements and trends.
OCGN Company Profile
Discover essential business fundamentals and corporate details for Ocugen, Inc. (OCGN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Dec 2014
Employees
95.00
Website
https://www.ocugen.comCEO
Shankar Musunuri
Description
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
OCGN Financial Timeline
Browse a chronological timeline of Ocugen, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is -$0.05, while revenue estimate is $976.14k.
Earnings released on 5 May 2026
EPS came in at -$0.06 falling short of the estimated -$0.05 by -20.00%, while revenue for the quarter reached $1.53m , beating expectations by +266.89%.
Earnings released on 4 Mar 2026
EPS came in at -$0.06 matching the estimated -$0.06, while revenue for the quarter reached -$193.00k , missing expectations by -117.95%.
Earnings released on 5 Nov 2025
EPS came in at -$0.07 falling short of the estimated -$0.06 by -21.74%, while revenue for the quarter reached $1.75m , beating expectations by +298.18%.
Earnings released on 1 Aug 2025
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%, while revenue for the quarter reached $1.37m , beating expectations by +357.67%.
Earnings released on 9 May 2025
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%, while revenue for the quarter reached $1.48m .
Earnings released on 5 Mar 2025
EPS came in at -$0.05 matching the estimated -$0.05, while revenue for the quarter reached $764.00k , beating expectations by +91.00%.
Earnings released on 8 Nov 2024
EPS came in at -$0.05 matching the estimated -$0.05, while revenue for the quarter reached $1.14m , beating expectations by +184.00%.
Earnings released on 8 Aug 2024
EPS came in at -$0.04 surpassing the estimated -$0.06 by +33.33%, while revenue for the quarter reached $1.14m .
Earnings released on 14 May 2024
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%, while revenue for the quarter reached $1.01m .
Earnings released on 26 Mar 2024
EPS came in at -$0.03 surpassing the estimated -$0.06 by +50.00%, while revenue for the quarter reached $6.04m .
Earnings released on 9 Nov 2023
EPS came in at -$0.06 surpassing the estimated -$0.08 by +25.00%.
Earnings released on 21 Aug 2023
EPS came in at -$0.10 falling short of the estimated -$0.08 by -25.00%.
Earnings released on 5 May 2023
EPS came in at -$0.07 surpassing the estimated -$0.11 by +36.36%, while revenue for the quarter reached $443.00k .
Earnings released on 28 Feb 2023
EPS came in at -$0.10 surpassing the estimated -$0.11 by +9.09%.
Earnings released on 8 Nov 2022
EPS came in at -$0.10 matching the estimated -$0.10.
Earnings released on 5 Aug 2022
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%.
Earnings released on 6 May 2022
EPS came in at -$0.09 falling short of the estimated $0.05 by -280.00%.
Earnings released on 25 Feb 2022
EPS came in at -$0.07 matching the estimated -$0.07.
Earnings released on 9 Nov 2021
EPS came in at -$0.05 falling short of the estimated -$0.04 by -25.00%.
Earnings released on 6 Aug 2021
EPS came in at -$0.13 falling short of the estimated -$0.03 by -333.33%.
OCGN Stock Performance
Access detailed OCGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
